EXPERIENCE OF TREATMENT WITH IBANDRONIC ACID IN PATIENTS WITH SEVERE RHEUMATOLOGICAL DISEASES AND SYSTEMIC OSTEOPOROSIS
Abstract
This article presents the results of a study of effectiveness and safety of ibandronic acid in 21 children with rheumatologic diseases and severe systemic osteoporosis. The treatment with ibandronic acid during 48 weeks provided statistically significant increase of mineral density of bones, decrease of pain intensity, lessening of serum concentration of bone resorption marker — C-terminal telopeptide. The development of repeated compressive fractures of vertebrae and bones of peripheral skeleton at the time of treatment with this medication was not detected.
Key words: children, rheumatological diseases, osteoporosis, treatment, bifosfonates, ibandronic acid.
(Voprosy sovremennoi pediatrii — Current Pediatrics. 2010;9(1):116-121)
About the Authors
A.O. LisitsynRussian Federation
E.I. Alexeeva
Russian Federation
V.G. Pinelis
Russian Federation
M.I. Bakanov
Russian Federation
S.I. Valieva
Russian Federation
T.M. Bzarova
Russian Federation
References
1. Cassidy J.T., Petty R.E., Laxer R.M., Lindsley C.B. Textbook of Pediatric Rheumatology. 5th ed. Philadelphia: W.B. Saunders. 2005.
2. Алексеева Е.И. Ревматические болезни и их влияние на качество жизни детей и их семей. Качество жизни. Медицина. 2008; 1: 14–17.
3. Fleurence R.L., Iglesias C.P., Johnson J.M. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. Pharmacoeconomics. 2007; 25 (11): 913–933.
4. Compston J. Clinical and therapeutic aspects of osteoporosis. Eur. J. Radiol. 2009; 71 (3): 388–391.
5. Geusens P. Osteoporosis: clinical features. Minerva Med. 2008; 99 (2): 167–175.
6. Brufsky A.M. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist. 2008; 13 (2): 187–195.
7. Di Munno O., Delle Sedie A. Effects of glucocorticoid treatment on focal and systemic bone loss in rheumatoid arthritis. J. Endocrinol. Invest. 2008; 31 (7): 43–47.
8. Wells G.A., Cranney A., Peterson J. et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst. Rev. 2008; 23(1): CD001155.
9. Haорis S.T., Blumentals W.A., Miller P.D. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. CuОР Med. Res. Opin. 2008; 24 (1): 237–245.
10. Russell R.G., Xia Z., Dunford J.E. et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann. N.Y. Acad. Sci. 2007; 17: 209–257.
11. Papapoulos S.E. Bisphosphonate actions: physical chemistry revisited. Bone. 2006; 38: 613–616.
12. Rudge S., Hailwood S., Horne A. et al. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford). 2005; 44 (6): 813–818.
13. Bianchi M.L., Cimaz R., Bardare M. et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum. 2000; 43 (9): 1960–1966.
14. Rudge S., Hailwood S., Horne A. et al. Effects of once weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford). 2005; 44: 813–818.
15. Алексеева Е.И., Лисицин А.О., Бзарова Т.М. и др. Эффективность и безопасность терапии алендроновой кислотой при остеопорозе у детей, страдающих юношеским артритом с системным началом. Педиатрическая фармакология. 2009; 1: 101.
16. Shaw N.J., Boivin C.M., Crabtree N.J. Intravenous pamidronate in juvenile osteoporosis. Arch. Dis. Child. 2000; 83 (2): 143–145.
17. Noguera A., Ros J.B., Pavía C.E. et al. Bisphosphonates, a new treatment for glucocorticoid induced osteoporosis in children. J. Pediatr. Endocrinol. Metab. 2003; 16 (4): 529–536.
18. Steelman J., Zeitler P. Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J. Pediatr. 2003; 142: 417–423.
19. Алексеева Е.И., Чистякова Е.Г., Лохматов М.М., Бзарова Т.М. Эффективность эзомепразола в лечении воспалительных заболеваний желудочно-кишечного тракта у детей с ревматическими болезнями. Вопросы современной педиатрии. 2007; 6 (1): 105–107.
Review
For citations:
Lisitsyn A., Alexeeva E., Pinelis V., Bakanov M., Valieva S., Bzarova T. EXPERIENCE OF TREATMENT WITH IBANDRONIC ACID IN PATIENTS WITH SEVERE RHEUMATOLOGICAL DISEASES AND SYSTEMIC OSTEOPOROSIS. Current Pediatrics. 2010;9(1):116-121.
Email this article 
